>> You owned both ENMD and ICOS? Need anybody to mow your lawn? << Thanks for the kind offer, Rick. I had ICOS from October and ENMD from November (I expected a spike then), but I also had DEPO and ALLP, so I had better mow my own lawn for a while yet.
All four of these were small positions, the ALLP one tiny (especially lately), My major pharma/biotech bets are SEPR, LGND, VVUS and ISIP, which will eventually tell me whether I've learned anything useful from you, Rman, V1, Peter Suzman, and the other contributors to SI threads I've followed for the last 15 months. I have a handful of other small positions, some of which I have a lot of hope for (MCDE, AXPH, XOMA, etc.) And I've started to nibble at INCY (under Rman's tutelage on this and the INCY thread) and CLTR. And I hope for more ideas on this very impressive thread.
As for portfolio ideas: Has anyone looked lately at VVUS (maker of Muse, the second best selling treatment for erectile dysfunction)?
I remember someone on this thread (V1? Rman?) last December (after VVUS had tanked form 40 to 10), suggesting VVUS and referring us to the VVUS thread, in particular the posts of Zebra365 and Tunica Albuginea. There wasn't much response on this thread, probably in part because the VVUS thread is almost as cluttered, nasty and exasperating as the LGND thread. Zebra has now published an article on VVUS, at techstocks.com
which I commend to you.
VVUS is very promising at these levels, I think: (1) VVUS is unreasonably cheap for identifiable reasons unrelated to its value, knocked down by transitory difficulties in expanding manufacturing capacity and by the dubious thought that Viagra will take the entire ED market (VVUS at 8 3/4 trades for 6-7 times likely earnings), (2) the hype over Viagra has alerted millions of men that treatment is now possible for ED, so that they will now talk to doctors for the first time about this embarrassing problem, (3) Viagra will not help maybe 30% of them, who will return to their doctors and be prescribed Muse, and (4) VVUS will sell all the Muse they can make, leading the earnings and the stock upwards, perhaps sharply upwards from these very depressed levels.
-- RCM |
